Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Abdul Hamid Bazarbachi; Daniel Reef; Hiba Narvel; Riya Patel; Rama Al Hamed; Sindhu Vikash; Karun Neupane; Eleftheria Atalla; Astha Thakkar; Shafia Rahman; Urvi Shah; Diego Adrianzen-Herrera; Ryann Quinn; Sumaira Zareef; Emma Rabinovich; Alyssa De Castro; Felisha Joseph; Kailyn Gillick; Jennat Mustafa; Fariha Khatun; Amanda Lombardo; Latoya Townsend-Nugent; Michelly Abreu; Nicole Chambers; Richard Elkind; Yang Shi; Yanhua Wang; Olga Derman; Kira Gritsman; Ulrich Steidl; Mendel Goldfinger; Noah Kornblum; Aditi Shastri; Ioannis Mantzaris; Liza Bachier-Rodriguez; Nishi Shah; Dennis Cooper; Amit Verma; Bihui Hilda Ye; Murali Janakiram; Roberto Alejandro Sica

doi:10.1007/s44228-023-00032-y

Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Abdul Hamid Bazarbachi, Daniel Reef, Hiba Narvel, Riya Patel, Rama Al Hamed, Sindhu Vikash, Karun Neupane, Eleftheria Atalla, Astha Thakkar, Shafia Rahman, Urvi Shah, Diego Adrianzen-Herrera, Ryann Quinn, Sumaira Zareef, Emma Rabinovich, Alyssa De Castro, Felisha Joseph, Kailyn Gillick, Jennat Mustafa, Fariha KhatunAmanda Lombardo, Latoya Townsend-Nugent, Michelly Abreu, Nicole Chambers, Richard Elkind, Yang Shi, Yanhua Wang, Olga Derman, Kira Gritsman, Ulrich Steidl, Mendel Goldfinger, Noah Kornblum, Aditi Shastri, Ioannis Mantzaris, Liza Bachier-Rodriguez, Nishi Shah, Dennis Cooper, Amit Verma, Bihui Hilda Ye, Murali Janakiram, Roberto Alejandro Sica

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Adult T-cell leukemia/lymphoma (ATLL) remains challenging to treat and has dismal outcome. Allogeneic stem-cell transplantation (allo-SCT) has promising results, but data remain scarce. In this single-center retrospective analysis of 100 patients with ATLL from north America (67 acute, 22 lymphomatous), 17 underwent allo-SCT and 5 autologous SCT (ASCT), with a median follow-up of 65 months. Post-transplant 3-years relapse incidence (RI) and non-relapse mortality (NRM) were 51% and 37%, respectively, and 3-year progression-free survival (PFS) and overall survival (OS) were 31% and 35%, respectively. ASCT 1-year RI was 80% compared to 30% in allo-SCT (p = 0.03). After adjusting for immortal-time bias, allo-SCT had significantly improved OS (HR = 0.4, p = 0.01). In exploratory multivariate analysis, patients achieving first complete response and Karnofsky score ≥ 90 had significantly better outcomes, as did Black patients, compared to Hispanics, who had worse outcome. In transplanted patients, 14 died within 2 years, 4 of which ASCT recipients. Our data are the largest ATLL transplant cohort presented to date outside of Japan and Europe. We show that allo-SCT, but not ASCT, is a valid option in select ATLL patients, and can induce long term survival, with 40% of patients alive after more than 5 years.

Original language	English (US)
Pages (from-to)	78-91
Number of pages	14
Journal	Clinical Hematology International
Volume	5
Issue number	2-3
DOIs	https://doi.org/10.1007/s44228-023-00032-y
State	Published - Jun 2023

Keywords

Adult T-cell leukemia/Lymphoma
Allogeneic stem-cell transplantation
Autologous stem-cell transplantation
Black
Hispanic
Human T-cell lymphotropic virus type I
Minority
North American

ASJC Scopus subject areas

Health Professions (miscellaneous)
Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s44228-023-00032-y

Cite this

Bazarbachi, A. H., Reef, D., Narvel, H., Patel, R., Al Hamed, R., Vikash, S., Neupane, K., Atalla, E., Thakkar, A., Rahman, S., Shah, U., Adrianzen-Herrera, D., Quinn, R., Zareef, S., Rabinovich, E., De Castro, A., Joseph, F., Gillick, K., Mustafa, J., ... Sica, R. A. (2023). Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. Clinical Hematology International, 5(2-3), 78-91. https://doi.org/10.1007/s44228-023-00032-y

Bazarbachi, AH, Reef, D, Narvel, H, Patel, R, Al Hamed, R, Vikash, S, Neupane, K, Atalla, E, Thakkar, A, Rahman, S, Shah, U, Adrianzen-Herrera, D, Quinn, R, Zareef, S, Rabinovich, E, De Castro, A, Joseph, F, Gillick, K, Mustafa, J, Khatun, F, Lombardo, A, Townsend-Nugent, L, Abreu, M, Chambers, N, Elkind, R, Shi, Y , Wang, Y, Derman, O, Gritsman, K , Steidl, U , Goldfinger, M , Kornblum, N , Shastri, A , Mantzaris, I, Bachier-Rodriguez, L, Shah, N , Cooper, D , Verma, A , Ye, BH, Janakiram, M & Sica, RA 2023, 'Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma', Clinical Hematology International, vol. 5, no. 2-3, pp. 78-91. https://doi.org/10.1007/s44228-023-00032-y

@article{bea1c699a1bd446f90fe796e30be8d71,

title = "Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma",

abstract = "Adult T-cell leukemia/lymphoma (ATLL) remains challenging to treat and has dismal outcome. Allogeneic stem-cell transplantation (allo-SCT) has promising results, but data remain scarce. In this single-center retrospective analysis of 100 patients with ATLL from north America (67 acute, 22 lymphomatous), 17 underwent allo-SCT and 5 autologous SCT (ASCT), with a median follow-up of 65 months. Post-transplant 3-years relapse incidence (RI) and non-relapse mortality (NRM) were 51% and 37%, respectively, and 3-year progression-free survival (PFS) and overall survival (OS) were 31% and 35%, respectively. ASCT 1-year RI was 80% compared to 30% in allo-SCT (p = 0.03). After adjusting for immortal-time bias, allo-SCT had significantly improved OS (HR = 0.4, p = 0.01). In exploratory multivariate analysis, patients achieving first complete response and Karnofsky score ≥ 90 had significantly better outcomes, as did Black patients, compared to Hispanics, who had worse outcome. In transplanted patients, 14 died within 2 years, 4 of which ASCT recipients. Our data are the largest ATLL transplant cohort presented to date outside of Japan and Europe. We show that allo-SCT, but not ASCT, is a valid option in select ATLL patients, and can induce long term survival, with 40% of patients alive after more than 5 years.",

keywords = "Adult T-cell leukemia/Lymphoma, Allogeneic stem-cell transplantation, Autologous stem-cell transplantation, Black, Hispanic, Human T-cell lymphotropic virus type I, Minority, North American",

author = "Bazarbachi, {Abdul Hamid} and Daniel Reef and Hiba Narvel and Riya Patel and {Al Hamed}, Rama and Sindhu Vikash and Karun Neupane and Eleftheria Atalla and Astha Thakkar and Shafia Rahman and Urvi Shah and Diego Adrianzen-Herrera and Ryann Quinn and Sumaira Zareef and Emma Rabinovich and {De Castro}, Alyssa and Felisha Joseph and Kailyn Gillick and Jennat Mustafa and Fariha Khatun and Amanda Lombardo and Latoya Townsend-Nugent and Michelly Abreu and Nicole Chambers and Richard Elkind and Yang Shi and Yanhua Wang and Olga Derman and Kira Gritsman and Ulrich Steidl and Mendel Goldfinger and Noah Kornblum and Aditi Shastri and Ioannis Mantzaris and Liza Bachier-Rodriguez and Nishi Shah and Dennis Cooper and Amit Verma and Ye, {Bihui Hilda} and Murali Janakiram and Sica, {Roberto Alejandro}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = jun,

doi = "10.1007/s44228-023-00032-y",

language = "English (US)",

volume = "5",

pages = "78--91",

journal = "Clinical Hematology International",

issn = "2590-0048",

publisher = "Saabron Press",

number = "2-3",

}

TY - JOUR

T1 - Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

AU - Bazarbachi, Abdul Hamid

AU - Reef, Daniel

AU - Narvel, Hiba

AU - Patel, Riya

AU - Al Hamed, Rama

AU - Vikash, Sindhu

AU - Neupane, Karun

AU - Atalla, Eleftheria

AU - Thakkar, Astha

AU - Rahman, Shafia

AU - Shah, Urvi

AU - Adrianzen-Herrera, Diego

AU - Quinn, Ryann

AU - Zareef, Sumaira

AU - Rabinovich, Emma

AU - De Castro, Alyssa

AU - Joseph, Felisha

AU - Gillick, Kailyn

AU - Mustafa, Jennat

AU - Khatun, Fariha

AU - Lombardo, Amanda

AU - Townsend-Nugent, Latoya

AU - Abreu, Michelly

AU - Chambers, Nicole

AU - Elkind, Richard

AU - Shi, Yang

AU - Wang, Yanhua

AU - Derman, Olga

AU - Gritsman, Kira

AU - Steidl, Ulrich

AU - Goldfinger, Mendel

AU - Kornblum, Noah

AU - Shastri, Aditi

AU - Mantzaris, Ioannis

AU - Bachier-Rodriguez, Liza

AU - Shah, Nishi

AU - Cooper, Dennis

AU - Verma, Amit

AU - Ye, Bihui Hilda

AU - Janakiram, Murali

AU - Sica, Roberto Alejandro

PY - 2023/6

Y1 - 2023/6

N2 - Adult T-cell leukemia/lymphoma (ATLL) remains challenging to treat and has dismal outcome. Allogeneic stem-cell transplantation (allo-SCT) has promising results, but data remain scarce. In this single-center retrospective analysis of 100 patients with ATLL from north America (67 acute, 22 lymphomatous), 17 underwent allo-SCT and 5 autologous SCT (ASCT), with a median follow-up of 65 months. Post-transplant 3-years relapse incidence (RI) and non-relapse mortality (NRM) were 51% and 37%, respectively, and 3-year progression-free survival (PFS) and overall survival (OS) were 31% and 35%, respectively. ASCT 1-year RI was 80% compared to 30% in allo-SCT (p = 0.03). After adjusting for immortal-time bias, allo-SCT had significantly improved OS (HR = 0.4, p = 0.01). In exploratory multivariate analysis, patients achieving first complete response and Karnofsky score ≥ 90 had significantly better outcomes, as did Black patients, compared to Hispanics, who had worse outcome. In transplanted patients, 14 died within 2 years, 4 of which ASCT recipients. Our data are the largest ATLL transplant cohort presented to date outside of Japan and Europe. We show that allo-SCT, but not ASCT, is a valid option in select ATLL patients, and can induce long term survival, with 40% of patients alive after more than 5 years.

AB - Adult T-cell leukemia/lymphoma (ATLL) remains challenging to treat and has dismal outcome. Allogeneic stem-cell transplantation (allo-SCT) has promising results, but data remain scarce. In this single-center retrospective analysis of 100 patients with ATLL from north America (67 acute, 22 lymphomatous), 17 underwent allo-SCT and 5 autologous SCT (ASCT), with a median follow-up of 65 months. Post-transplant 3-years relapse incidence (RI) and non-relapse mortality (NRM) were 51% and 37%, respectively, and 3-year progression-free survival (PFS) and overall survival (OS) were 31% and 35%, respectively. ASCT 1-year RI was 80% compared to 30% in allo-SCT (p = 0.03). After adjusting for immortal-time bias, allo-SCT had significantly improved OS (HR = 0.4, p = 0.01). In exploratory multivariate analysis, patients achieving first complete response and Karnofsky score ≥ 90 had significantly better outcomes, as did Black patients, compared to Hispanics, who had worse outcome. In transplanted patients, 14 died within 2 years, 4 of which ASCT recipients. Our data are the largest ATLL transplant cohort presented to date outside of Japan and Europe. We show that allo-SCT, but not ASCT, is a valid option in select ATLL patients, and can induce long term survival, with 40% of patients alive after more than 5 years.

KW - Adult T-cell leukemia/Lymphoma

KW - Allogeneic stem-cell transplantation

KW - Autologous stem-cell transplantation

KW - Black

KW - Hispanic

KW - Human T-cell lymphotropic virus type I

KW - Minority

KW - North American

UR - http://www.scopus.com/inward/record.url?scp=85149862200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149862200&partnerID=8YFLogxK

U2 - 10.1007/s44228-023-00032-y

DO - 10.1007/s44228-023-00032-y

M3 - Article

AN - SCOPUS:85149862200

SN - 2590-0048

VL - 5

SP - 78

EP - 91

JO - Clinical Hematology International

JF - Clinical Hematology International

IS - 2-3

ER -

Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this